Sartorius continues to grow by double digits
Growth dynamics of the Lab Products & Services Division impacted by softer European demand
Sartorius continued on the growth track, with double-digit gains in sales revenue and earnings.
“In the first nine months of 2018, Sartorius achieved excellent organic growth,” said Dr. Joachim Kreuzburg, Chief Executive Officer. “This applies particularly to the Bioprocess Solutions Division, which grew dynamically across all product categories and geographies. For the Lab Products & Services Division, growth in the third quarter was below our expectations due to softer demand in Europe. At the Group level, however, this effect will be largely compensated for by the strong development of our bioprocess business so that we confirm our ambitious full-year forecast.”
Business development of the Sartorius Group
In the first nine months of 2018, Sartorius increased its sales revenue by 13.4% in constant currencies to 1,153.7 million euros (reported: 10.9%). The majority of growth was achieved organically, while acquisitions contributed close to 1.5 percentage points. In the same period, order intake also increased significantly, up 13.3% to 1,215.2 million euros.
Geographically, all regions contributed to consolidated growth. Especially in the Americas, sales revenue rose significantly by 20.1% to 387.9 million euros against a moderate prior-year base, and Asia|Pacific again saw double-digit growth of 13.4% to 281.7 million euros, despite strong performance in the previous year. EMEA recorded a solid gain of 8.6% to 484.1 million euros (all growth rates for the regions and order intake in constant currencies).
The Sartorius Group also substantially increased its earnings in the first nine months of 2018. Underlying EBITDA rose overproportionately relative to sales by 15.0% to 294.2 million euros; the respective margin was 25.5% compared with 24.6% a year ago. Relevant net profit for the Group grew significantly by 21.8% to 126.3 million euros. Earnings per ordinary share totaled 1.84 euros (9M 2017: 1.51 euros) and earnings per preference share 1.85 euros (9M 2017: 1.52 euros).
The Group's key financial indicators continued to remain at robust levels. At the end of the reporting period, the company's equity ratio was 35.6%, and its ratio of net debt to underlying EBITDA stood at 2.4 (Dec. 31, 2017: 35.1% and 2.5, resp.). The capex ratio was 13.0%, slightly below the year-earlier figure of 13.6%. Investment activities continued to focus on expansion of the plant for manufacturing single-use bags and filters in Puerto Rico, as well as on the consolidation and expansion of Group headquarters in Göttingen, Germany.
Business development of the divisions
The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacture of biopharmaceuticals, recorded double-digit growth in sales revenue and order intake in the first nine months of 2018. After the previous year’s comparably moderate performance, momentum considerably picked up in the reporting period. The division’s sales revenue rose in constant currencies by 14.8% to 843.0 million euros (reported: 12.2%) and was driven by strong demand for equipment and single-use products. The increase in sales revenue was achieved almost completely organically, whereas the software company Umetrics acquired in April 2017 contributed around half a percentage point of non-organic growth. Order intake also rose at a very dynamic rate by 15.0% to 901.8 million euros.
Despite negative currency effects, and driven by economies of scale and positive product mix effects, underlying EBITDA of the Bioprocess Solutions Division rose overproportionately relative to sales, by 16.5% to 239.1 million euros. The Group's respective margin increased significantly year over year from 27.3% to 28.4%.
The Lab Products & Services Division, which offers laboratory technologies primarily for the pharma sector and life science research, recorded an increase in sales revenue in constant currencies by 9.7% to 310.7 million euros (reported 7.4%), following high growth in the prior-year period. After a strong first half, development was dampened in the third quarter as a result of softer demand in Europe. Finalized in March 2017, the acquisition of Essen BioScience, a specialist in cell analysis, contributed non organic growth of close to 3.5 percentage points in line with expectations. The division’s nine-month order intake grew in constant currencies by 8.7% to 313.4 million euros.
Underlying earnings for Lab Products & Services rose 9.0% to 55.0 million euros. Despite negative currency effects, the division's earnings margin increased slightly from 17.5% to 17.7%, which was driven by economies of scale and product mix effects.
Full-year guidance confirmed; division forecasts adjusted
In view of the company’s performance in the first nine months of 2018, management confirms its full-year projections, substantially raised at mid-year, that consolidated sales will grow by about 12% to 15%. The Group’s underlying EBITDA margin remains forecasted to increase by about 0.5 percentage points compared with the year-earlier figure of 25.1%.
Based on the dynamic growth recorded for the Bioprocess Solutions Division in the reporting period, management now projects that the division’s sales revenue will increase at the upper range of the previously targeted bandwidth of about 12% to 15%. This figure includes a non-organic growth contribution of slightly less than 0.5 percentage points. The division's underlying EBITDA margin is forecasted to further gain about half a percentage point over the prior-year figure of 28.0%.
For the Lab Products & Services Division, management reduces growth projections for sales due to softer demand in Europe, to 8% to 10% (previous guidance: about 12% to 15%). Essen BioScience consolidated since March 2017 is forecasted to contribute a good 2.5 percentage points of non-organic growth, as expected so far. The division’s underlying EBITDA margin is projected to further rise; due to the division’s lower sales growth, however, this increase will now be around half a percentage point over the prior-year figure of 18.0% (previous forecast: one percentage point).
All forecasts are based on constant currencies. As a result of changes in the currency exchange rates, reported figures in actual currencies may differ from constant currency guidance.
Other news from the department business & finance
Groundbreaking: Takeda builds lab of the future in Vienna
New research and development laboratory in Vienna's Donaustadt district
Biosynth Extends its Offering to Multi-Kilogram GMP Peptide Synthesis through the Acquisition of Pepceuticals
traceless materials secures €36.6 Million Series A to build first industry plant for bio-circular alternative to plastic
Change-enabler for driving the green transformation of the industry
Cytomos welcomes new Director
£4 million investment sets path for commercialisation of groundbreaking cell analysis technology
Beckman Coulter and Fujirebio enter into partnership
The goal is a patient-friendly, blood-based Alzheimer's disease test
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success
Successful exit: adivo joins Zoetis
adivo’s team and platform will strengthen Zoetis’ capabilities in therapeutic antibody drug discovery for companion animals
Bertelsmann Investments acquires stake in AI-powered Israeli healthcare startup QuantHealth
AI-supported start-up company for clinical trial planning
Moderna and Immatics Announce Strategic Multi-Platform Collaboration
Develop Innovative Oncology Therapeutics
Microplate Dx secures £2.5 million to develop rapid diagnostic technology for better antibiotic use
In minutes rather than days to prescribe the optimal antibiotic
RIANA Therapeutics enters into collaboration agreement with LDC
"This cooperation has the great potential to lay the groundwork for new, urgently needed therapeutic approaches for AML patients"
Six companies enter BioInnovation Institute's Venture House program receiving additional financial support
AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage
Life Science Factory to Open a New Location at Helmholtz Munich in 2024
Strategic partnership between Life Science Factory and Helmholtz Munich to promote spin-offs
Most read news
Cells with an ear for music release insulin
For the first time, researchers are using music, including Queen's global hit "We will rock you," to stimulate insulin release from cells
Microbe of the Year 2023: Bacillus subtilis – for health and technology
Already, Bacillus subtilis is indispensable in many industries, and many more innovations are expected
Younger generation gets sick earlier and more often than older generation
In spite of their advanced age, they are in the middle of life, healthy, active and mentally alert – they are referred to as the “young old”
How sleep deprivation can harm the brain
Sleep deprivation decreases the amount of a factor that protects neurons
New approach to testing for long Covid
Blood vessels in the eye altered with persistent coronavirus symptoms
A whole new order of bacteria could hold the key to improving biogas production
The discovery was made by researchers from Germany, Spain and the Netherlands
How to inactivate common cold viruses
In the cold season, cold viruses are everywhere. But we can do something about it
How minimal genetic differences can turn healthy food into a deadly danger
You are what you eat - this old saying could take on a new dimension according to latest research results
At which age we are at our happiest
An evaluation of over 400 samples shows how subjective well-being develops over the course of a lifespan
New compound unleashes the immune system on metastases
A new nanocomplex renders a tumor harmless – and, on top of that, it trains the immune system to detect and eliminate metastases
More news from our other portals
Major breakthrough in the development of electric vehicle batteries
New study finds ways to suppress lithium plating in automotive batteries for faster charging electric vehicles
Clean water from fog
A property known as photocatalytic memory ensures that this also functions when skies are overcast and at night
Research shows table salt could be the secret ingredient for better chemical recycling
Table salt as the key to the plastics recycling revolution?
Green, sweet and crisp - New apple variety Pia41 approved
The apple bred at the Julius Kühn Institute receives variety protection
Benchtop NMR spectroscopy can accurately analyse pyrolysis oils
More accessible analysis could help develop the potential of bio-oils as an alternative to fossil fuels
Graphene discovery could help generate hydrogen cheaply and sustainably
Microscopic insights into electrochemical interfaces
Sugar: Small increase in production despite record prices
EU sugar market more than in need of reform to keep medium-sized processing companies competitive
Leipzig-based start-up converts CO₂ into green chemicals with patented plasma catalysis
CO₂ recycling as a useful complement to carbon capture and storage
New battery holds promise for green energy
Redox-flow battery eliminates costly and inefficient membrane
A microchip for Parmigiano Reggiano cheese
Consorzio del Parmigiano Reggiano, p-Chip Corporation, and Kaasmerk Matec Partner to Launch Breakthrough in Food-Safe Digital Tracking Technology
Scientists use quantum device to slow down simulated chemical reaction 100 billion times
What happens in femtoseconds in nature can now be observed in milliseconds in the lab
A Second Life for Electric Car Batteries
Scientists develop a decision model for retired lithium-ion batteries
Fondant under the magnifying glass
New insights into the properties of sweet coating: The results could be used to optimize the industrial production process in the future
World record: World's longest-range electric car comes from Munich
Electric car drives over 2500 kilometres on a single battery charge
Green methanol for shipping and industry: € 10.4 Mio. for the "Leuna100" project
A consortium of two Fraunhofer institutes, DBI-Gastechnologisches Institut Freiberg, Technical University of Berlin and C1 makes industrial history at the Leuna site
Making plant-based meat more ‘meaty’ — with fermented onions
When fermented with specific type of fungus, normally pungent onions can produce the same sort of chemicals that make meats smell ‘meaty’